New RSV shot for babies enters early human trials
NCT ID NCT07363837
First seen Jan 23, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This study tests a new medicine called SIBP-A16 to see if it can safely prevent RSV in infants under 1 year old, including those born early. About 36 babies will receive either the new drug, a placebo, or an existing RSV drug. The main goal is to check for side effects and how the drug behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Second Hospital, Sichuan University
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIBP-A16 injection
What this could lead to
If successful, this could lead to a new option to protect infants from severe RSV infection during their first season.
What could go wrong
This is a very early, small trial (36 infants) focused on safety and dosing. The drug may not prove effective or could have side effects, and results may not apply to all infants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.